Starfire Ventures will focus on early-stage AI-native businesses, while Serena Ventures has stopped making new investments.
Flagship puts £100 million behind British AI biotech venture lab
The firm aims to draw at least £500 million from partners and initially recruit about 50 scientist-entrepreneurs and operators in Britain.

Flagship Pioneering said on November 16 it is putting £100 million into a British laboratory to build and fund biotech businesses using artificial intelligence. The London-based operation will be its first company-building lab beyond the United States.
Founder and CEO Noubar Afeyan said Flagship would create businesses rather than take stakes in existing companies. It plans to pursue university, corporate and funding partnerships, with the aim of attracting £500 million or more alongside its own commitment.
The Flagship Origination lab will operate from the firm's London office, which opened in 2023. Flagship expects its initial recruitment in Britain to include about 50 scientist-entrepreneurs and operators.
Afeyan said the National Health Service and its patient data were Britain's main attractions. Those resources enable researchers to identify disease targets using real-world evidence before working on medicines, he said.
The lab will use AI across its activities, including invention and clinical trials, Afeyan said, while cautioning that the technology's use in the field remains early. Generate Biomedicines, a Flagship company, has completed an early-stage Manchester trial involving an AI-designed asthma drug.
Flagship has created more than 130 companies, among them Moderna. Before the British expansion, it had operated solely in the United States for more than 25 years.
